Keeping the Workforce: the Drug Industry's Cognitive Dissonance Problem
Executive Summary
Amidst the mounting attacks on the drug industry by respected mass market publications and broadcast news, it is growing increasingly difficult for those in the industry to maintain the personal mission of "doing good" that--at least partly--attracted them to the pharmaceutical business. In the past, attractive option packages might have helped executives deal with uneasiness about some of the strategies being pursued by companies under the gun of blockbuster economics. But with stock prices low, that source of comfort has been removed--raising doubts about the industry's ability to retain its best and brightest.
You may also be interested in...
The Value of Me-Too's in the Context of OTC Switches
At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.